Myer Vickesh 4
4 · Editas Medicine, Inc. · Filed Feb 22, 2019
Insider Transaction Report
Form 4
Myer Vickesh
Chief Technology Officer
Transactions
- Sale
Common Stock
2019-02-20$20.42/sh−3,000$61,260→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2019-02-20−3,000→ 76,307 totalExercise: $0.65Exp: 2025-04-29→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2019-02-20$0.65/sh+3,000$1,950→ 3,000 total
Footnotes (3)
- [F1]The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
- [F2]This transaction was executed in multiple trades at prices ranging from $20.31 to $20.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- [F3]This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.